Differences

This shows you the differences between two versions of the page.

--- home:physicians:concerns [02.09.2019] – [Numerical improvements update] sallieq
+++ home:physicians:concerns [07.10.2019] – [Concerns about lack of clinical evidence] sallieq
@@ Line 1: / Line 1: @@
 ====== Physicians' concerns about the Marshall Protocol ======
+<relatedarticle> [[home:starting:physician:reluctant#specific_research|Section  to print off - Independant research into Olmesartan with PMIDs for doctor.]] </article>
 Over the years, physicians have voiced various concerns about the Marshall Protocol, concerns ranging from the safety of higher doses of olmesartan (Benicar) to concerns about long-term antibiotic use. The Autoimmunity Research Foundation has assembled articles, well-grounded in scientific research, which address these concerns. Physicians who choose to use and administer the MP do so on the basis of the [[home:physicians:concerns#concerns_about_lack_of_clinical_evidence|available evidence]].
@@ Line 5: / Line 7: @@
 ===== Concerns about lack of clinical evidence =====
-  - **"There are no well-controlled studies to support the use of the Marshall Protocol for a given indication."** This statement is accurate. At this point, patients and physicians who choose to use and administer the MP do so based on the following evidence:
+  - **"There are no well-controlled studies to support the use of the Marshall Protocol for a given indication."** This statement is accurate. In 2012, patients and physicians who chose to use and administer the MP did so based on the following evidence:
     * a [[home:publications:proal_molecular_2011|2011 case series of MP patients]] appearing in the (Nature Publishing Group) journal //Clinical & molecular immunology//
     * a [[home:publications:mp2008_survey|2008 retrospective survey]] of 100 MP patients with autoimmune diagnoses
@@ Line 15: / Line 17: @@
 For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment:
-  * evidence for the efficacy of MP versus other available treatment options(({{pubmed>long:19050187}}))
+  * alternative hypotheses and evidence of research (({{pubmed>long:    15246025}})), (({{pubmed>long:16403216}})), (({{pubmed>long:23370376}})), (({{pubmed>long:18200565}}))
+  * evidence for the efficacy of MP versus other available treatment in 2013 data on patient response, see section below
   * patients' expressed preferences and values(({{pubmed>long:19050187}}))
   * additional benefits of Olmesartan [[https://mpkb.org/home/protocol/olmesartan#other_benefits_of_olmesartan_in_patients_-_recent_studies|other researched benefits]]
@@ Line 24: / Line 27: @@
 <html></p></div></html>
-===== Numerical improvements update =====
+===== Recorded results assessed 2013  =====
 <blockquote>//DJ posted// :- During the summer of 2013 I looked at 2,000 records of people using the Marshall Protocol.</blockquote>
-See [[home:patients:cohort_statistics#later information|significant information]] pertaining to 864 patients //who maintained the Marshall Protocol over a sufficient number of years and continued to report to the study site//.
+Resulting in [[home:patients:cohort_statistics#later information|significant information]] pertaining to 864 patients //who maintained the Marshall Protocol over a sufficient number of years and continued to report to the study site//.
+<blockquote> I tried my best to be unbiased as I was expecting to see about a 20% improvement in health of members, or in other words a 20-25% success rate.
+I was intending to compare this to the 10% success rate I found done on the use of prednisone to treat Sarcoidosis. That double blind report shows that 10% treated with prednisone achieve remission. (BTW remission in Sarcoidosis as far as I can find out is measured rather subjectively)
+(This) is what I found:
+Sarcoidosis: 236 members; 179 success; 25 no success; 32 unsure
+Chronic Fatigue Syndrome: 183 members; 110 success; 30 no success; 43 unsure
+Lyme Disease: 169 members; 113 success; 23 no success; 33 unsure
+Rheumatoid arthritis: 39 members; 27 success; 5 no success; 7 unsure
+Fibromyalgia: 53 members; 34 success; 6 no success; 13 unsure
+Other Th1 diseases: 184 members; 110 success; 30 no success 44 unsure
+TOTALS: 864 members;573 report success; 119 report no success; and for 172 results are not clear.
+SUCCESS RATES: Over all success rate 66.32% Over all unsuccessful 13.77% Over all unsure 19.91%
+Sarcoidosis success 75.8%
+Chronic Fatigue Syndrome success 60.1%
+Lyme disease success 66.9%
+Rheumatoid arthritis success 69.2%
+Fibromyalgia success 64.2% </blockquote>
 ===== Concerns about olmesartan (Benicar) =====
@@ Line 71: / Line 106: @@
 ==== Read also ====
+[[http://electromagnetichealth.org/wp-content/uploads/2012/04/EMF-Guideline.pdf|Guideline of the Austrian Medical Association for the diagnosis and treatment of EMF-related health problems and illnesses (EMF syndrome) ]]
 **Evaluation of the Effect of Radiofrequency Radiation Emitted From Wi-Fi Router and Mobile Phone Simulator on the Antibacterial Susceptibility of Pathogenic Bacteria Listeria monocytogenes and Escherichia coli.**\\ Altogether, the findings of this study showed that exposure to Wi-Fi and RF simulator radiation can significantly alter the inhibition zone diameters and growth rate for L monocytogenes and E coli. These findings may have implications for the management of serious infectious diseases.  (({{pubmed>long:28203122}}))
@@ Line 78: / Line 115: @@
-{{tag>resources_for_physicians}}
+{{tag>resources_for_physicians research}}
+[[home:starting:physician:reluctant#Specific_research|Section  to print off - Independent research into Olmesartan with PMIDs for doctor.]]
 ===== Notes and comments =====

home/physicians/concerns.txt · Last modified: 09.14.2022 by 127.0.0.1